Integrated early-phase hVIVO offers an integrated early-phase ecosystem combining clinical sites, virology and immunology labs, human challenge expertise, and development consulting, creating a single-source partner for sponsors seeking rapid, decision-ready Phase I/II data.

Large-cap client base With seven of the world's ten largest biopharma companies in its global client base, hVIVO presents a strong foothold for expanding collaborations, cross-sell of services (clinical, lab, consulting), and longer-term program commitments.

Specialized facilities London quarantine facilities and Germany-based early-phase capacity position hVIVO as a unique provider for controlled human challenge studies and rapid recruitment, appealing to sponsors prioritizing speed, safety, and regulatory alignment.

Therapeutic breadth Dominant capabilities in respiratory and infectious diseases with growing exposure to cardiometabolic areas suggest opportunities to package multi-therapy program offerings and expand into adjacent high-growth modalities.

Data-driven acceleration Continuous patient recruitment through FluCamp and integrated labs enable faster data generation and decision-making for Phase I/II programs, a compelling value proposition for sponsors aiming to de-risk early development and shorten timelines.